• Publications
  • Influence
Clinical diagnostic criteria for dementia associated with Parkinson's disease
Clinical diagnostic criteria for probable and possible PD‐D are proposed, characterized by impairment in attention, memory, executive and visuo‐spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent.
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
Criteria that support the diagnosis of progressive supranuclear palsy, and that exclude diseases often confused with PSP, are presented.
Criteria for the diagnosis of corticobasal degeneration
Clinical CBD phenotypes and features were combined to create 2 sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based pathologies.
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD, but this knowledge should be applied with caution in the diagnosis and counselling of patients.
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
  • B. Dubois, D. Burn, +18 authors M. Emre
  • Psychology, Medicine
    Movement disorders : official journal of the…
  • 15 December 2007
The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment.
Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study
It is indicated that in people presenting to sleep centres, RBD often antedates the development of a neurodegenerative disorder, which may be of great interest when early effective treatment strategies and neuroprotective drugs become available.
Validation of the freezing of gait questionnaire in patients with Parkinson's disease
FOG‐Q was a reliable tool for the assessment of treatment intervention and was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility.
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease
This study provides an iPSC‐based in vitro model that captures the patients' genetic complexity and allows investigation of the pathogenesis of both sporadic and familial PD cases in a disease‐relevant cell type.
BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies.
The present results demonstrate selective decline of the BDNF/TrkB neurotrophic signaling pathway in the frontal cortex and hippocampus in AD and provide supplemental data that may be relevant in discussing the suitability of the use of BDNF as a therapeutic agent in patients with AD.
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised,
Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone.